287 results on '"Hagner, Patrick"'
Search Results
2. Correction: Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma
3. Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma
4. Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1
5. Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy
6. Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study
7. Extended exposure to low doses of azacitidine induces differentiation of leukemic stem cells through activation of myeloperoxidase
8. P-360 Exploring the role of the polycomb repressive complex 2 in high-risk multiple myeloma
9. P1211: TUMOR-ACTIVATED LYMPH NODE FIBROBLASTS SUPPRESS T CELL FUNCTION IN DIFFUSE LARGE B CELL LYMPHOMA
10. P997: FEDRATINIB IS EFFECTIVE IN RUXOLITINIB-RESISTANT CELLS: CLINICAL AND PRECLINICAL CORRELATIONS
11. Tumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma
12. A Novel BCMA Immunohistochemistry Assay Reveals a Heterogenous and Dynamic BCMA Expression Profile in Multiple Myeloma
13. Supplementary Table 1 from A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
14. Supplementary Table 2 from A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
15. Supplementary Table 3 from A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
16. Supplementary Data from A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies
17. Supplementary Figure 1 from A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
18. Supplementary Figure Legends 1-2, Tables1-3 from Identification of Transformation-Related Pathways in a Breast Epithelial Cell Model Using a Ribonomics Approach
19. Data from Extracellular Signal-Regulated Kinase Positively Regulates the Oncogenic Activity of MCT-1 in Diffuse Large B-Cell Lymphoma
20. Data from Identification of Transformation-Related Pathways in a Breast Epithelial Cell Model Using a Ribonomics Approach
21. Supplementary Figures 1-2 from Identification of Transformation-Related Pathways in a Breast Epithelial Cell Model Using a Ribonomics Approach
22. Supplementary Figures 1-4 from Extracellular Signal-Regulated Kinase Positively Regulates the Oncogenic Activity of MCT-1 in Diffuse Large B-Cell Lymphoma
23. Tumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma
24. CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL
25. Biological Features of a High-Risk Transcriptional Molecular Subtype in Diffuse Large B-Cell Lymphoma
26. Suppression of Myeloid Cell-Derived Proinflammatory Cytokines with Celmod Agents: Implications for CRS with T-Cell Engagers (TCEs)
27. Fedratinib Induces Cytokine Changes Correlating with Clinical Response in Ruxolitinib Exposed Myelofibrosis Patients: Biomarker Analysis from the Freedom Trial
28. P-230: Preclinical and translational biomarker analysis to support further clinical development and dose optimization of mezigdomide (MEZI; CC-92480) in combination with either bortezomib or carfilzomib
29. Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell‐mediated cytotoxicity
30. Interactome of Aiolos/Ikaros Reveals Combination Rationale of Cereblon Modulators with HDAC Inhibitors in DLBCL
31. ATM regulates a DNA damage response posttranscriptional RNA operon in lymphocytes
32. Phase Ib study of avadomide (CC‐122) in combination with rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma and follicular lymphoma
33. Phase Ib study of combinations of avadomide (CC‐122), CC‐223, CC‐292, and rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma
34. Targeting the translational machinery as a novel treatment strategy for hematologic malignancies
35. CC-92480 Enhances Cell-Autonomous Cytotoxicity through Blockade of G 2/M Transition When Combined with Bortezomib/Dexamethasone in Pre-Clinical Multiple Myeloma
36. Differential Effects of Iberdomide Versus Revlimid on Leukocyte Trafficking, Immune Activation and DLBCL Tumor Cell Killing
37. Low Exposure Extended Dosing Mimicking Clinical Exposures of the Oral Formulation of Azacitidine Results in a Sustained Hypomethylation and Targets Leukemic Stem Cells
38. Pre-Clinical and Clinical Immunomodulatory Effects of Pomalidomide or CC-92480 in Combination with Bortezomib in Multiple Myeloma
39. Discovery of Prolyl-tRNA Synthetase As a Novel Target in Multiple Myeloma
40. Alcohol consumption and decreased risk of non-Hodgkin lymphoma: role of mTOR dysfunction
41. Targeted suppression of MCT-1 attenuates the malignant phenotype through a translational mechanism
42. Abstract 3165: Stroma-immune landscape in lymphoma: new mechanisms of immunosuppression and therapeutic targeting
43. Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1 /PD-1 immunotherapy
44. Investigation of the Synergistic Combination of a Novel Celmod (CC-99282) and BET Inhibitors in Preclinical DLBCL
45. A Multiomic Single-Cell Atlas of Human Myelopoiesis Reveals Cellular and Molecular Drivers of Immunomodulatory Drug-Induced Neutropenia
46. Emergence of Highly-Plastic B Cell States Cooperates with Early Immune Microenvironment Remodeling to Drive Follicular Lymphomagenesis
47. Mezigdomide Reverses T-Cell Exhaustion through Degradation of Aiolos/Ikaros and Reinvigoration of Cytokine Production Pathways
48. Celmod Induced Disruption of Granulopoiesis Continuum Identified Using Humanized Cereblon Mice
49. Differential Chromatin Organization between t(4;14) and Non-t(4;14) Multiple Myeloma Driven By the Histone Methyltransferase NSD2
50. Fedratinib Overcomes Ruxolitinib Resistance through Inhibition of the Interferon Signaling Pathway
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.